Caris Life Sciences Launches New Blood Test for Early Cancer Detection
The test utilizes genomic sequencing and AI to identify biological signals associated with early-stage disease.
The test utilizes genomic sequencing and AI to identify biological signals associated with early-stage disease.
A study reports that an OpenAI reasoning model improved rare disease diagnostic yield by 4.8% in previously unsolved cases, offering new leads after specialist analysis.
The system simultaneously detects RSV, influenza A and B, and SARS-CoV-2 from a nasal swab in under 10 minutes.
Monitoring circulating tumor DNA dynamics outperformed standard markers for predicting survival and relapse in early-stage patients.
Read MoreThe study demonstrated that patients who test positive for ctDNA “actually benefit from chemotherapy.”
Read MoreResearch shows optical genome mapping identifies genomic changes in nearly 98% of T-cell acute lymphoblastic leukemia cases compared to 55% with traditional analysis.
Read MoreResults from the NHS-Galleri study show a 26% reduction in metastatic cancer diagnoses by the third round of screening.
Read MoreThe test uses a new approach to identify signs of cancer recurrence with faster result times for healthcare providers and patients.
Read MoreThe new 3B-NEO service uses whole exome and whole genome sequencing to identify risks for serious childhood-onset disorders before symptoms appear.
Read MoreClinical results show high sensitivity for colorectal cancer relapse and ultra-low detection limits for lung cancer.
Read MoreResults from the PATHFINDER 2 trial show the Galleri test identifies 6.5 times more cancers when used with standard screenings.
Read MoreUpdated criteria integrate clinical manifestations and genetic testing to reduce the time required to reach an informed diagnosis.
Read MoreThe integrated electrophoresis solution is designed to simplify routine verification by eliminating gel casting and buffer preparation.
Read MoreThe multicenter study will evaluate proactive outreach to at-risk relatives and the impact of multigene panel testing on patient care.
Read MoreThe Callisto Sample Prep System application is optimized for the PromethION platform to support whole genome sequencing workflows.
Read MoreThe settlement follows a criminal conviction and addresses more than $174 million in fraudulent Medicare claims involving multiple laboratories.
Read MoreThe funding will support commercial expansion of the company’s blood-based diagnostic tests and the appointment of a new president and chief operating officer.
Read MoreResearch presented at ESTRO 2026 suggests circulating tumor DNA can identify which patients will benefit from combined radiation and drug therapy.
Read More